Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLB1 | P16278 | 1/20 | 0.68 |
| ▸ | GBA1 | P04062 | 6/20 | 0.60 |
| ▸ | GUSB | P08236 | 2/20 | 0.59 |
| ▸ | GBA2 | Q9HCG7 | 8/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | UGCG | Q16739 | 3/20 | 0.41 |
| ▸ | MGAM | O43451 | 2/20 | 0.41 |
| ▸ | SI | P14410 | 2/20 | 0.41 |
| ▸ | AGL | P35573 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20016395 | 1.00 | GLB1 (0.68) | GLB1GBA1GUSBGBA2GAA | |
| SCHEMBL27867099 | 0.91 | GLB1 (0.57) | GLB1GBA1GUSBGBA2GAA | |
| SCHEMBL6860086 | 0.89 | GLB1 (0.66) | GLB1GBA1GUSBGBA2GAA | |
| SCHEMBL3378984 | 0.82 | GLB1 (1.00) | GLB1GBA1GUSBGBA2GAA | |
| SCHEMBL2437297 | 0.82 | GLB1 (1.00) | GLB1GBA1GUSBGBA2GAA | |
| SCHEMBL2435887 | 0.82 | GLB1 (1.00) | GLB1GBA1GUSBGBA2GAA | |
| SCHEMBL2435892 | 0.82 | GLB1 (1.00) | GLB1GBA1GUSBGBA2GAA | |
| SCHEMBL3234285 | 0.82 | GLB1 (0.91) | GLB1GBA1GUSBGBA2GAA | |
| SCHEMBL2435889 | 0.82 | GLB1 (1.00) | GLB1GBA1GUSBGBA2GAA | |
| SCHEMBL22030799 | 0.76 | GLB1 (0.38) | GLB1GBA1GUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143875-B1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS INC (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-3143875-B1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS INC (US) | 2020-05-27 | — | — | EP | disclosed |
| US-10421724-B2 | Compositions for preventing and/or treating degenerative disorders of the central nervous system | AMICUS THERAPEUTICS, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| EP-2995306-B1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS INC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180334432-A1 | Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-11-22 | — | — | US | disclosed |
| US-20180273474-A1 | Novel Compositions For Preventing And/Or Treating Degenerative Disorders Of The Central Nervous System | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-09-27 | — | — | US | disclosed |
| US-10035766-B2 | Compositions for preventing and/or treating lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035766-B2 | Compositions for preventing and/or treating lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035766-B2 | Compositions for preventing and/or treating lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-9931353-B2 | Method for treating cerebral amyloid angiopathy using pharmacological chaperones to increase the activity of gangliosidases | AMICUS THERAPEUTICS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20120309788-A1 | Method for Treating Alzheimer's Disease Using Pharmacological Chaperones To Increase The Activity of Gangliosidases | AMICUS THERAPEUTICS, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2011049736-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011049787-A1 | METHOD FOR TREATING ALZHEIMER'S DISEASE USING PHARMACOLOGICAL CHAPERONES TO INCREASE THE ACTIVITY OF GANGLIOSIDASES | AMICUS THERAPEUTICS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011049737-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20110092541-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092541-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092541-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110091442-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110091442-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110091442-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309788-A1 | Method for Treating Alzheimer's Disease Using Pharmacological Chaperones To Increase The Activity of Gangliosidases | GBA1, GBA3, ASAH1 | GLB1 69/4885GBA1 1/4885GUSB 42/4885 |
| US-20180273474-A1 | Novel Compositions For Preventing And/Or Treating Degenerative Disorders Of The Central Nervous System | GAP43, CHAT, PMP22 | GLB1 1946/4885GBA1 337/4885GUSB 1603/4885 |
| US-10421724-B2 | Compositions for preventing and/or treating degenerative disorders of the central nervous system | PMP22, GAP43, CHAT | GLB1 1881/4885GBA1 306/4885GUSB 1895/4885 |
| US-20180334432-A1 | Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders | GAA, GBA1, MAN2B1 | GLB1 39/4885GBA1 2/4885GUSB 57/4885 |
| US-20110091442-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | GAA, GBA1, MAN2B1 | GLB1 39/4885GBA1 2/4885GUSB 57/4885 |
| US-20110092541-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | GAP43, CHAT, PMP22 | GLB1 1946/4885GBA1 337/4885GUSB 1603/4885 |
| US-10035766-B2 | Compositions for preventing and/or treating lysosomal storage disorders | GAA, GBA1, MAN2B1 | GLB1 30/4885GBA1 2/4885GUSB 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.